KALA Levels + Short Info
Short squeeze stocks have become a favorite recently. KALA has started getting wrapped into the conversation. Looking at details from sites like FinViz, short float is around 20% meanwhile the float itself shows to be around 42 million shares. Plotting some levels, you'll notice that KALA is still in the lower channel on the fib retracement slowly heading toward the 786 area. However, before that happens, keep watch on an interim level around $3.40. It was previously a support level in July but seems to have become a resistance level as KALA was strongly rejected right at $3.40 on Friday. Aside from the technical/speculative trend, there are also a few things to watch with the company after a rough first half:
"Kala specializes in eye treatments. Its EYSUVIS is quickly playing a leading role for the company. According to the company, this past quarter, it was a preferred prescription for short-term treatment of dry eye disease. Furthermore, Kala explained that its expanding market access with Commercial and Medicare Part D health plans...Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals, explained, “We are encouraged by the very positive feedback we consistently receive from physicians and patients, who describe EYSUVIS as an effective and comfortable medicine and look forward to building on this foundation as we continue with the EYSUVIS launch. In parallel, we continue to promote INVELTYS and are advancing our pipeline of new chemical entities for front and back of the eye diseases, as we work to build a robust and sustainable portfolio of innovative treatments.”"
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
"Kala specializes in eye treatments. Its EYSUVIS is quickly playing a leading role for the company. According to the company, this past quarter, it was a preferred prescription for short-term treatment of dry eye disease. Furthermore, Kala explained that its expanding market access with Commercial and Medicare Part D health plans...Mark Iwicki, Chairman, President, and Chief Executive Officer of Kala Pharmaceuticals, explained, “We are encouraged by the very positive feedback we consistently receive from physicians and patients, who describe EYSUVIS as an effective and comfortable medicine and look forward to building on this foundation as we continue with the EYSUVIS launch. In parallel, we continue to promote INVELTYS and are advancing our pipeline of new chemical entities for front and back of the eye diseases, as we work to build a robust and sustainable portfolio of innovative treatments.”"
Quote Source & Read More: 4 Short Squeeze Penny Stocks To Watch After SPRT Stock’s 1,309% Run
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.